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ABSTRACT
Objectives To assess the accuracy and completeness 
of information provided by websites selling home self- 
sampling and testing kits for COVID-19.
Design Cross- sectional observational study.
Setting All websites (n=27) selling direct to user home 
self- sampling and testing kits for COVID-19 (41 tests) 
in the UK (39 tests) and USA (two tests) identified by a 
website search on 23 May 2020.
Main outcome measures Thirteen predefined basic 
information items to communicate to a user, including who 
should be tested, when and how testing should be done, 
test accuracy, and interpretation of results.
Results Many websites did not provide the name or 
manufacturer of the test (32/41; 78%), when to use the 
test (10/41; 24%), test accuracy (12/41; 29%), and how to 
interpret results (21/41; 51%). Sensitivity and specificity 
were the most commonly reported test accuracy measures 
(either reported for 27/41 [66%] tests): we could only link 
these figures to manufacturers’ documents or publications 
for four (10%) tests. Predictive values, most relevant to 
users, were rarely reported (five [12%] tests reported 
positive predictive values). For molecular virus tests, 
9/23 (39%) websites explained that test positives should 
self- isolate, and 8/23 (35%) explained that test negatives 
may still have the disease. For antibody tests, 12/18 
(67%) websites explained that testing positive does not 
necessarily infer immunity from future infection. Seven 
(39%) websites selling antibody tests claimed the test had 
a CE mark, when they were for a different intended use 
(venous blood rather than finger- prick samples).
Conclusions At the point of online purchase of home 
self- sampling COVID-19 tests, users in the UK are 
provided with incomplete, and, in some cases, misleading 
information on test accuracy, intended use, and test 
interpretation. Best practice guidance for communication 
about tests to the public should be developed and enforced 
for online sales of COVID-19 tests.
INTRODUCTION
The 2019 novel coronavirus (COVID-19) 
pandemic has resulted in national popula-
tion measures such as restricted movement 
(‘lockdown’), and mass testing programmes. 
Testing is regarded as critical to manage the 
pandemic – the two main test types available 
being molecular virus tests (to detect current 
infection) and antibody tests (to detect 
previous infection). The WHO recommends 
polymerase chain reaction (PCR)- based 
molecular virus testing of symptomatic indi-
viduals to detect current COVID-19 infec-
tion,1 to enable identification and isolation 
of confirmed cases, and tracing of those 
exposed for further testing. However, due to 
the sensitivity for a single PCR test being as 
low as 70%,2 the WHO states that even two 
consecutive negative PCR tests do not rule 
out infection with COVID-19.1 Antibody tests 
are not recommended for individual use by 
Strengths and limitations of this study
 ► We believe this is the first research on accuracy of 
information provided by websites selling tests for 
COVID-19, where users may put themselves or oth-
ers at increased risk of transmission if results are 
misinterpreted.
 ► We duplicated processes of searching and data ex-
traction to minimise bias.
 ► Using pre- specified criteria, we found evidence that 
websites selling home self- sampling COVID-19 tests 
provided incomplete and inaccurate information on 
test accuracy and interpretation of test results at the 
point of purchase.
 ► We developed basic guidance on what should be 
communicated when selling tests, including the 
type of test; situations when the test should be used; 
the time when the test should be done and details 
of how it should be done; the name of the test and 
details from clinical accuracy studies; evidence of 
compliance with regulatory approvals; explanation 
of test results using accessible and relevant metrics 
such as predictive values; and guidance to the inter-
pretation and actions based on results.
 ► We only included websites from the UK and USA, 
so while the principles of what should be commu-
nicated apply to all countries, the results about data 
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the WHO, because we do not yet understand whether 
the presence of antibodies infers immunity from future 
infection. Their sensitivity has been estimated at around 
80%–90%, thus there is also a risk of false negatives.3 
Timing of testing is critical for both tests: molecular tests 
are thought to be most accurate when used within 5 days 
of the onset of symptoms,4 antibody tests are most accu-
rate 2 or more weeks after onset of symptoms.3
There are now multiple websites selling both molecular 
virus tests and antibody tests outside of national testing 
programmes. To ensure appropriate use, interpretation 
and actions following testing, it is necessary for tests to 
be sold with clear communication about who should use 
each test, when and how samples should be taken, and 
the implications of positive and negative results. Previous 
research investigating direct to user sales of genetic 
testing found that the information provided was incom-
plete, particularly the implications of test results and 
limitations of testing, and was not always in an accessible 
and understandable format.5–7
Direct to user sale of tests are regulated by the Medicines 
and Healthcare products Regulatory Agency (MHRA) in 
the UK and the Food and Drug Administration (FDA) 
in the USA. Europe8 and the USA9 operate a risk- based 
regulation for in vitro diagnostic devices (IVDs) which 
depends on the intended use of the test and indications 
for use. IVDs for home testing fall into higher risk catego-
ries reflecting the fact they are initiated, performed, and 
interpreted without professional guidance and require 
evidence that lay users correctly use the test and under-
stand the test results. Lay user studies are required as the 
basis for the instructions for use (IFU) document for the 
IVD.10 Home sampling tests are different from home testing 
as they receive approval based on home collected speci-
mens with the test analysis being undertaken by profes-
sionals. At the time of writing, there were no COVID-19 
antibody tests with a CE mark for either home sampling 
or home testing11 (the two COVID-19 antibody tests 
purchased by the UK Government are approved for 
use in venous but not finger- prick blood samples) while 
several molecular virus tests have regulatory approval 
for home sampling and are being used in the UK track 
and trace programme.12 Most websites selling COVID-19 
tests would be classified by the MHRA as ‘distributors’, 
which gives clear obligations to supply the information 
provided by manufacturers with the test, but no specific 
guidance around communication on the website at the 
point of sale. Such claims are covered by the Advertising 
Standards Agency. In the US, there are no COVID-19 anti-
body tests with regulatory approval for home testing but 
four molecular (PCR) virus tests that have approval for 
home sampling13 where the appropriateness of the test 
purchase is assessed by a professional either pre- purchase 
or following a purchase request.
We analysed the information given to individuals 
considering purchasing a molecular virus or antibody 
COVID-19 test online for home self- sampling. We chose 
to review tests for sale in both the UK and USA to cover 
two different regulatory systems with contrasting health 
services. We recorded information regarding who should 
be tested and when, claims about test accuracy, and infor-
mation about how to interpret results. As the MHRA 
instigated a withdrawal of sales of antibody tests based on 
finger- prick blood samples on 29 May 2020 where tests 
require venous blood samples,11 we also evaluated how 
test vendors have responded.
METHODS
Our research question was how complete, accurate, and 
informative is the information that online websites selling 
home self- sampling and testing kits for COVID-19 provide 
to the public?
Identification of websites
The search was designed to identify a representative 
sample of websites and online advertisements which 
would be seen by an individual searching for a non- 
specific COVID-19 test. We aimed to identify websites 
selling home self- sampling and testing for COVID-19 
using molecular virus and/or antibody tests directly to 
users. Two researchers performed the searches inde-
pendently on the same day (23 May 2020) using the 
Google search engine in incognito mode in Google 
Chrome, with geo- locations for the UK and for the USA. 
In order to emulate a simple search for a non- specific 
coronavirus test, the search terms were (coronavirus OR 
covid-19 OR covid19) AND (test OR testing OR kit). Two 
researchers independently screened all results against the 
inclusion criteria, and disagreements were resolved by a 
third researcher. For the UK search, we included websites 
moved to the top of the search results through advertise-
ments, in order to mirror what a user would have seen on 
that day.
Inclusion criteria
We included websites selling molecular virus and/or anti-
body tests for COVID-19 direct to users in either the USA 
or UK. We included point- of- care and laboratory- based 
tests, with the proviso that the sample was taken at home 
by the individual themselves. We excluded tests with 
assisted sampling (eg, drive- through testing), or where 
part of the testing process before purchase included 
video, telephone, or in- person contact with a medical 
professional (as we could not objectively assess the 
information content of such interactions). We included 
websites selling tests both via direct purchase and insur-
ance funding, but excluded local or national government 
websites providing tests (including Public Health England 
[PHE] and the UK National Health Service [NHS]), 
and websites providing tests as part of a research study. 
We included all eligible tests, including where a single 
website sold multiple eligible tests. We excluded websites 
with a minimum order of more than a single test, as these 
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Data extraction
We extracted information about the test manufac-
turer and type of test; when testing was recommended; 
claims made about test accuracy; the advice given about 
changing behaviour in light of test results; accreditation; 
and the test cost. We assessed the information provided 
against a predefined list of items which we would expect 
to be communicated to a person considering purchasing 
a test for COVID-19, detailed in table 1.
We extracted claims made about regulatory approval of 
the tests, in particular CE- IVD approval in the UK and 
FDA approval in the USA, and where possible compared 
claims to the actual approval status for the test. We 
also extracted claims made about approval from non- 
regulatory bodies such as PHE and the NHS.
Website contents were extracted between 23 and 28 May 
2020. One researcher extracted data from each website 
onto a predefined data extraction form, and downloaded 
the website as a pdf file. A second researcher checked each 
extraction using the pdf copy to exclude temporal changes.
Patient and public involvement
A public contributor (MS), with both experience of being 
involved in research and leading public involvement in 
research, provided input into this project. MS has an 
interest in communicating scientific information to lay 
audiences. The rapid timeframes in which the research 
was conducted limited the scope for more comprehensive 
public involvement. MS contributed to discussions and 
paper drafts and is included as a co- author.
Ethics approval was not required for this review of 
publicly available documents.
RESULTS
For the UK our Google searches retrieved 550 results, 
and for the USA they retrieved 430 results. After the first 
round of sifting by two reviewers 46 potentially eligible 
websites were identified. Of these 19 websites were later 
excluded, 13 of which only sold in quantities greater than 
one or to laboratories/hospitals/workplaces, five who 
incorporated contact with a health professional before 
the sale, and one which was withdrawn from sale between 
the search and extraction. We identified 23 molec-
ular virus testing services14–36 and 18 antibody testing 
services14–16 18 19 21 25 26 28 29 31–34 37–40 meeting the inclusion 
criteria, sold via 27 websites (25 from the UK14–34 37–40 and 
two from the USA.35 36 One website40 did not appear in 
the main search, but was mentioned in many UK news 
articles, so was included in the cohort. Only two websites 
using home sampling were identified in the USA, the first 
and second to be approved by the FDA for this use.35 36 
Basic characteristics of the websites and tests are given in 
online supplemental table 1.
The websites consisted of 13 private health 
clinics,14–17 20 21 24–26 29 36 38 39 four pharmacies,30 32 34 40 
four suppliers of a range of direct to consumer testing 
online,18 22 31 37 three laboratories,23 33 35 two online sexual 
health specialists19 27, and one supplier of beauty treat-
ments.28 All 23 molecular virus tests were laboratory- 
based tests with home sampling. Of the 18 antibody tests, 
17 were laboratory- based tests with home self- sampling, 
and one was a point- of- care test.38 The test manufacturer 
was identifiable for 9/41 (22%) tests, and further details 
are provided in online supplemental figure 1.
The mean cost of molecular virus testing was £168 
(range £65 to £279) in the UK and $135 (range $119 to 
$150) in the USA. The mean cost of antibody tests was 
£87 (range £55 to £130) in the UK.
The proportion of websites which met each of the criteria 
for clear communication (outlined in table 1) is shown in 
figure 1, and examples of reporting are given in table 2.
Explaining which test and when to test
All 27 websites stated whether the 41 tests for sale were 
molecular virus tests or antibody tests, of which 40/41 
described the test clearly. Guidance on timing of taking 
the molecular virus tests and the antibody tests was 
provided by 15/23 (65%)15 17–21 25–27 29–31 34–36 and 16/18 
(89%)15 16 18 19 21 25 26 28 29 31 33 34 37–40 websites, respectively. 
Recommendations on timing and variation in timing of 
sampling are detailed in figure 2, with several contrary to 
current advice or opinion.4
Test accuracy and interpretation
Of the 41 tests for sale, the websites reported a measure 
of test accuracy (sensitivity, specificity, positive or nega-
tive predictive value) for 27 (66%) tests: 16/18 (89%) 
for antibody tests14 15 18 19 21 25 26 28 29 31 33 34 37–40 and 11/23 
(48%) for molecular tests.14 17 20–22 25 26 33–36 An additional 
10/41 (24%) tests (two antibody16 32 and eight molec-
ular tests15 16 18 19 23 27 29 32 only reported test performance 
using unclear terms such as ‘accuracy’ or ‘reliability’, for 
example “This test has a 99.9% accuracy”19 and “This test 
offers 99.9% reliability.”29 Tests with unclear performance 
values may be referring to analytical performance, such 
as “Our test is sensitive to fewer than 100 copies of the target 
viral RNA, making it a highly accurate test.”32 For two (5%) 
molecular tests, no text or values referring to accuracy 
were reported on the websites.24 31
Sensitivity and specificity were the most 
commonly reported accuracy measures, provided 
for 27/41 (66%)14 15 17–22 25 26 28 29 31 33–40 and 22/41 
(54%)15 17 19–22 25 26 28 29 31 33–37 39 40 tests, respectively. Sensi-
tivity estimates ranged from 95% to 100% for antibody 
tests (n=16)14 15 18 19 21 25 26 28 29 31 33 34 37–40 and 97.5% to 
100% for molecular tests (n=11).14 17 20–22 25 26 33–36 Speci-
ficity estimates ranged from 97.5% to 100% for antibody 
tests (n=13)15 19 21 25 26 28 29 31 33 34 37 39 40 and were reported as 
100% for all molecular tests (n=9).17 20–22 25 26 34–36 Five of 
the 41 tests (13%; two antibody tests28 31 and three molec-
ular14 20 33 tests) provided an estimate or statements of 
sensitivity and/or specificity under conditions of perfect 
use rather than pragmatic use, for example “If there are any 
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Table 1 Predefined information items which we would expect to be communicated to a person considering purchasing a test 
for COVID-19, and misinformation items which we would consider inappropriate to communicate, with rationale
Information item Rationale
Who should take the test?
  1. Does the website clearly explain whether it is a 
test for antibodies (whether you have previously 
had the disease) or active virus (whether you have it 
now)?
To help the potential purchaser select the most appropriate test type.
  2. Does the website explain when to test? Accuracy is heavily dependent on timing. Antibody tests undertaken 
too early have low sensitivity (they make false negative errors, that is, 
miss cases of COVID-19). Molecular virus tests undertaken very early 
or too late have reduced sensitivity.
Test accuracy information
  3. Can you identify the test which is used? that is, 
the manufacturer
There has been significant media coverage of the accuracy of different 
manufacturers’ tests. Providing this information enables those 
interested to find out more.
  4. Does the website give accuracy to detect cases? 
(sensitivity)
An informed potential purchaser would want to ensure tests 
successfully identify COVID-19.
  5. Does the website give accuracy to detect non- 
cases? (specificity)
An informed potential purchaser would want to ensure tests did not 
misidentify COVID-19.
  6. Does the website state how many samples the 
accuracy claims are based on?
Accuracy data based on few samples is less reliable. While few people 
may be interested in the detail of the test accuracy study design, the 
number of samples/patients may be of interest.
  7. Does the website give information on the post- 
test probability of having or ruling out the disease? 
(Positive predictive value or negative predictive value 
at any prevalence)
This is the most important accuracy information for a person 
considering buying a test. For an individual whose molecular virus 
test result is positive, the positive predictive value gives them the 
probability that they currently have COVID-19. For an individual whose 
molecular virus test is negative, the negative predictive value is the 
probability that they do not currently have COVID-19. For an individual 
whose antibody test is positive, the positive predictive value is the 
probability that they have COVID-19 antibodies. For an individual 
whose antibody test is negative the negative predictive value is the 
probability that they do not have COVID-19 antibodies. These metrics 
are dependent on disease prevalence as well as sensitivity and 
specificity, but can reasonably be calculated with informed estimates 
of prevalence.
  8. Does the website give a link or reference to a 
journal article of test accuracy?
Indicating the source of these data would help substantiate the 
claims, and allow interested people to find out more.
Avoiding misinformation about interpreting the test
  9. Molecular virus test – does the website avoid the 
inaccurate statement that if you test negative you are 
not infectious or do not need to self- isolate?
The molecular virus tests are not very sensitive and so negative results 
may be false negatives, so the individual may still have the virus and 
be contagious.
  10. Antibody test – does the website avoid the 
inaccurate statement that we know that test positive 
infers immunity or allows you to put yourself at 
greater risk of virus exposure?
A positive antibody test could be a false positive, meaning the 
individual does not have antibodies. Even if it is a true positive we do 
not know whether the presence of antibodies infers immunity, and 
how that changes over time as antibody levels drop.
Providing accurate information about interpreting the test
  11. Molecular virus test – does the website state that 
if you test positive you should self- isolate?
Individuals who test positive on a molecular virus test are likely to 
have active virus, and are likely to be contagious.
  12. Molecular virus test – does the website state that 
if you test negative you may still have the disease?
Same rationale as item 9 above, but here we assessed whether 
the websites gave correct information (in addition to avoiding 
misinformation).
  13. Antibody test – does the website explain that we 
do not know whether a positive test infers immunity, 
and/or that you shouldn’t put yourself at more risk of 
exposure if you test positive?
Same rationale as item 10 above, but here we assessed whether 
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No websites directly referred to positive predictive 
values (PPV), but they were indirectly reported for 5/41 
(12%) tests.20 21 25 25 40 Two antibody25 40 and three molec-
ular tests20 21 25 made a statement about the lack of false 
positives (implying a PPV of 100%), for example “if it 
shows a positive result, it can only be for COVID-19”.25 No 
cross- reactivity (meaning the test would not identify other 
viruses, only COVID-19 virus) was referred to by websites 
for 13/41 (32%) tests (five antibody16 25 33 34 40 and eight 
molecular tests).17 20–22 25 26 28 34 Negative predictive value 
(NPV) was not referred to by any websites, however, state-
ments implying that the NPV was less than 100% were 
given for 4/41 (10%) available tests (two antibody25 31 
and two molecular tests,20 35) for example “The test can 
sometimes show a negative result even if you are infected [with] 
SARS- CoV-2, the virus that causes COVID-19.”35
The number of samples used to generate accuracy data 
were given for 5/41 (12%) tests: two antibody tests31 33 and 
three molecular tests.22 35 36 Accuracy data were linked to a 
journal publication for only 1/41 (2%) tests.33
Information on interpreting both positive and nega-
tive molecular virus test results was presented for 4/23 
(17%) websites.20 33–35 Twelve of the 18 (67%) websites 
selling antibody tests informed potential customers prior 
to purchase that a positive antibody test may not infer 
immunity from future infection14 16 18 21 25 28 32–34 37 39 40 
(figure 1).
Where tests could be identified, we checked accuracy 
claims against data from published papers, pre- prints 
(based on information obtained from searches from 
ongoing Cochrane reviews for these tests), and manufac-
turer’s data in the IFU sheet for each test (table 3). Four 
websites reported clinical performance data for the Abbott 
IgG antibody test: two31 33 quoted the performance figures 
from the IFU,41 for the other two26 29 no exact match with 
available studies could be made. Of the four molecular 
tests, no performance data were available for the Randox 
test23 (including in the IFU,42 no direct match of clinical 
performance results could be made for the website selling 
the Primerdesign genesig PCR assay),22 where the IFU 
only reported data from contrived samples,43 whereas the 
data reported by US websites35 36 selling the LabCorp and 
Rutgers PCR tests, respectively, matched data from the 
manufacturers’ IFUs.44 45
Claims about regulatory approval and endorsement
Across the 25 UK websites, there were 17 antibody tests 
for home sampling,14–16 18 19 21 25 26 28 29 31–34 37 39 40 one 
antibody test for home testing38 and 21 molecular tests 
for home sampling14–34 for sale. There was no mention 
of regulatory approval or endorsement for 18/39 (46%) 
tests, seven antibody tests14 16 26 28 32 39 40 and 11 molecular 
tests14 16 18 19 22–24 27 29–31 (see online supplemental table 1).
For home sampling antibody tests, 7/17 (41%) included 
a statement that the test had a CE mark15 19 21 25 33 34 37 and 
7/17 (41%) websites included a clear statement that the 
test had endorsement from a policy making body such 
as PHE, the NHS, or the UK or other European govern-
ments.15 18 21 29 31 33 34 This is despite the fact that currently 
no COVID-19 antibody tests have regulatory approval 
for home sampling or home testing. Claims being made 
about home sampling tests were based on approved test 
use by health professionals using venous rather than 
finger- prick samples:
"All of our home test kits are CE- marked. This is one 
of the two IgG tests approved by the Government for 
UK use."15
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Table 2 Examples of clear/accurate and unclear/potentially misleading website content
Information item
Example of unclear/potentially misleading 
information
Example of clearer and more accurate 
communication
Who should take the 
test?
“you can do the swab test between 1–5 days post 
exposure."34
This is likely to be too early for the PCR molecular 
virus test specified to be sufficiently sensitive. Median 
time between exposure and symptom onset is 
around 5 days,54 so this proposed timing is likely pre- 
symptomatic when sensitivity is lower.
“Ideally samples should be taken from 
symptomatic individuals between days 1–5 
from symptom onset. However, there are many 
cases when virus can be detected later into the 
illness."20
It would also be helpful to communicate that 
taking the test too early or late when it is less 
accurate may result in the test missing COVID-19 
when it is present.
Test accuracy “This test offers 99.9% reliability"29
“What is the accuracy of the test? 99.9%"29
It is unclear what the terms ‘accuracy’ or ‘reliability’ 
mean.
No website provided a full explanation of 
accuracy, we suggest our own example as 
follows (data provided for example and text can 
be amended to clearly indicate molecular or 
antibody tests)
“Test accuracy: The tests are sometimes 
inaccurate. If you have a negative result 
(indicating you have not got COVID-19) then 
the test is very likely to be correct. If you 
get a positive result (indicating you have got 
COVID-19) then the result is less accurate. 
Of the people who test positive, 92 in 100 do 
actually have COVID-19. Of the people who 
test negative, more than 99 in 100 do not have 
COVID-19. Here is more detail on the science: 
Test accuracy was measured in an independent 
evaluation of 158 people with COVID-19 and 364 
people without COVID-19 (give reference for the 
underlying evidence). The test had a sensitivity 
of 98% and a specificity of 99.2%. That means 
that if 1000 people are tested, and 100 of those 
have COVID-19, then 98 of the 100 people 
with COVID-19 will be detected and two will be 
missed (test negative). Of the 900 people who 
do not have COVID-19, 892 will test negative, 
and eight will test positive (and believe they have 
COVID-19 when they do not).“
Interpreting test 
results of molecular 
virus tests
“This highly accurate test will give you peace of mind 
that you can't infect others. This test is relevant when 
people who have been isolating wish to return to their 
household, community or workplace and need to 
know that they aren't infectious”16
This refers to the PCR molecular virus test, which 
is known to have low sensitivity so people testing 
negative may still be infected and infectious to others.
Reasons for taking the PCR test cited as “You need 
to know if you are infectious or not” and “You want to 
let your household members know if they need to self- 
isolate”25
“If you have tested positive for COVID-19, self- 
isolation is recommended so that you do not 
pass the virus to others…If your results are 
negative and you’re having symptoms, continue 
to follow isolation precautions and ask your 
healthcare provider if you need further testing.”35
Linking information on the low negative 
predictive value of the PCR test to 
recommendations to continue self- isolation may 
strengthen the message.
Interpreting test 
results of antibody 
tests
"A positive test result indicates that you have been 
exposed to COVID-19 and your immune system has 
produced antibodies in response to the virus. If you 
have had no symptoms for at least 7 days, you should 
have some level of immunity to COVID-19 and may 
not be able to transmit the virus to others or become 
infected by it again."19
We do not currently know whether the presence of 
antibodies infers immunity.
“There is still a great deal about COVID-19 
immunity that we do not yet fully understand… 
If your IgG test is positive it means you have 
had COVID-19 exposure sufficiently to make an 
antibody response to the virus. There is currently 
no scientific evidence confirming if the presence 
of antibodies correlates to immunity or how long 
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One website38 claimed it had regulatory approval for its 
home testing antibody test:
"Our test has been accepted by Medicines and 
Healthcare products Regulatory Agency (MHRA), 
which means that it can be applied across the EU in-
cluding UK. We confirm our product can meet the 
requirement of in vitro Diagnostic Medical Devices 
Directive (98/79EC) and standards complying with 
CE Declaration of Conformity."38
Five of 21 (24%) UK websites selling molecular virus 
tests for home sampling included a statement that 
they had regulatory approval,15 21 25 26 33 and six (29%) 
websites17 20 28 32–34 claimed approval from a policy making 
body for this intended use. The manufacturer or name of 
the molecular tests for which websites were claiming regu-
latory approval or endorsement could not be identified. 
Only for two websites selling molecular tests,22 23 the test 
manufacturer could be identified, neither of which made 
any claims about regulation or endorsement. One of 
these tests23 is mentioned by the UK government as part 
of its COVID-19 testing strategy46 and the other22 was one 
of the tests which was independently evaluated by PHE.47
Both US websites selling molecular viral tests35 36 have 
approval from the FDA for home sampling during the 
COVID-19 pandemic. These websites included informa-
tion about the eligibility checks that purchasers would 
need to undergo either prior to purchase or prior to test 
processing.
We reviewed the 18 UK websites selling home COVID-19 
antibody tests14–16 18 19 21 25 26 28 29 31–34 37–40 on 11/12 June 
2020 after the MHRA had instructed sales of these tests to 
cease because of the lack of approval for the tests using 
finger- pick samples.11 We found two websites32 38 that 
appeared to still be selling finger- prick tests, four14 21 28 31 
had switched to providing a venous blood sampling service, 
two18 33 required the purchaser to find their own phle-
botomist to draw a blood sample to send, six15 16 19 25 34 40 
simply stated that tests were out of stock and were unavail-
able, while four26 29 37 39 reported the MHRA guidance and 
indicated that they had suspended sales (table 4).
DISCUSSION
We identified 27 websites selling COVID-19 tests direct to 
the public, 25 in the UK but only two in the USA, which 
may be explained by the FDA stipulations requiring clini-
cian involvement in the testing process. We observed that 
many websites failed to provide complete information on 
the name and manufacturer of the test (no information 
for 32/41 tests), when to use the test (no information for 
10/41 tests), the accuracy of the test (no information for 
12/41 tests), and how to interpret results (no informa-
tion for 21/41 tests), which will hinder the public making 
informed choices about testing, using tests correctly and 
understanding what test results mean. Without adequate 
and correct information the public may purchase the 
wrong or a poor test, or use the test in the wrong way 
or at the wrong point in time. These errors or applica-
tions will increase their chances of getting an erroneous 
test result. Even when used properly, few websites assisted 
users in interpreting test results and understanding their 
inherent uncertainty.
This rapid evaluation was designed to provide timely 
results in the context of a fast- moving global pandemic. 
The search was not designed to be exhaustive, rather 
to represent what a person typing “coronavirus test” or 
similar into a Google search would have retrieved. Using 
Figure 2 Recommendations given by websites on when to take the molecular virus tests and antibody tests. Test accuracy is 
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different phrases such as “coronavirus antibody test” 
would have identified additional websites, but there is 
no reason to suspect that they would be different from 
those summarised here. The timing of the search and 
data extraction will have affected results. Data extraction 
was shortly before the UK MHRA clarified that antibody 
tests were not approved for finger- prick samples, only 
for venous samples. The search only identified two US 
websites selling tests with home sample collection, but at 
the point of going to press eight tests are now approved 
on the FDA website.48 The criteria that we used to assess 
completeness of communication (detailed in table 1) 
were defined a priori, but due to time constraints a formal 
process for developing these was not followed. However, 
all key elements of the search, selection, and data 
extraction processes were undertaken independently by 
two researchers, reducing the possibility of errors. We 
only assessed information provided prior to purchase, 
as complete information should be given at this stage 
to inform the purchasing decision. However, further 
information would have been given after purchase, for 
example within the instructions for use, which was beyond 
the scope of this paper.
The issues we have identified are examples of poor and 
misleading practice, and some merit further investigation 
by the MHRA and Advertising Standards Authority (ASA). 
At the time of going to press two antibody tests remained 
on sale and we have reported these to the MHRA. The 
communication of test accuracy appears to contravene 
advertising standards in the UK. The five websites that 
reported PPV of 100% contrary to the wider evidence 
base, and all websites making accuracy claims which is 
not linked to supporting evidence appear to contravene 
section 12.1 of the ASA code,49 which states that objec-
tive claims must be backed by evidence. Further, websites 
provided specificity and sensitivity, or general claims of 
‘accuracy’ rather than positive and negative predictive 
values explained in lay terms, and the ASA have previ-
ously ruled against this practice as misleading in the case 
of non- invasive prenatal testing for trisomies.50 Finally, 
the lack of complete information on the implications of 
positive and negative test results does not appear to be 
covered by any UK regulation, perhaps because the ASA 
12.2.149 prohibits diagnosis by post or email, and so this 
information is intended to be provided by contact with a 
healthcare professional. While such contact with a health 
professional is happening in the USA it does not appear 
to be in the UK. Regulation of product labelling provides 
a means to oversee information communicated for self- 
testing products bought in person, but there is currently 
no equivalent for online testing services in the UK. This 
gap in regulation could be solved by expanding the 
responsibility of the MHRA to include communication 
by ‘distributors’ at the point of online purchase, working 
collaboratively with the ASA. There was a large varia-
tion in the price of testing in the UK, and in many cases 
these differences do not appear to be justified by differ-
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Table 4 Availability of finger- prick antibody tests post- MHRA withdrawal from market notice (websites accessed on 11 to 12 
June 2020)
Website Status Comments
PillDoctor32 Still available Test appears to still be available for purchase
YourHealthFirst Clinic38 Still available Test appears to still be available for purchase
Summerfield Healthcare16 Not currently available Webpage suggests finger- prick antibody test still available but 
not available in subsequent drop down menu.
Doctorcall15 Not currently available “Coming soon”
Option on website to be notified when product is back in stock
WebMed Pharmacy34 Not currently available “Sorry the item you have selected is not currently available, please 
choose another option”
“Due to the high demand of orders, the antibodies blood test 
service is currently not available.”
Superdrug40 Not currently available "We have temporarily halted the COVID-19 antibody testing 
service. If you have any questions please send us a message 
through your account.”
Zava25 Out of stock “This product is temporarily out of stock.”
Option on website to be notified when product is back in stock
Better2Know19 Out of stock “Currently out of stock”
Website links to guidance from MHRA.
Antibody Solutions28 Out of stock/ modified test “Please note: these kits are no longer in stock; however, we are 
offering a full blood sample collection service, either at your home 
or at one of our partner clinics.”
Blue Horizon Medicals18 Modified test "Ordering this test will allow us to send you a vacutainer kit, 
which allows a healthcare professional to draw a venous blood 
sample from your arm. You should only order this kit therefore if 
you have access to a healthcare professional with the appropriate 
skills. Phlebotomy should NOT be attempted by those who are 
unskilled.”
Qured21 Modified test “A healthcare professional will visit your home to take a venous 
blood sample.”
"The antibody tests currently used by our laboratory are the 
Abbott test if you opt for venous blood collection by a healthcare 
professional, or the Siemens test if you opt to collect your blood 
sample yourself”
“These tests are currently validated for venous blood draw only, 
which is why our service includes an at- home blood draw from 
a healthcare professional. Home self- collection of blood using a 
finger- prick kit for antibody testing has been temporarily paused 
pending evaluation by the Medicines and Healthcare products 
Regulatory Agency (MHRA).”
CityDoc14 Modified test “We are able to offer blood collection by the normal practice of 
intravenous blood sampling at our clinics across the UK and sent 
to our accredited UK laboratory for testing.”
Atruchecks Limited31 Modified test “PHE approved Abbott test in our accredited lab. Venous sample 
taken in central London clinic, off Harley Street (W1).”
London Medical Laboratory33 Modified test “This option is so you can arrange a home or workplace visit by a 
phlebotomist to take your blood for you.”
The Online Clinic (Online 
Clinic (UK) Limited)26
Suspended/ modified test “The self- collect home sampling service is currently suspended 
but will be back shortly. Please check back later.”
"The Medicines and Healthcare Regulatory Agency is currently 
conducting a review of self- collect blood samples for this type of 
test and the service is unavailable until that review concludes. We 
now offer a home- sampling service where a phlebotomist attends 
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standardisation of website claims may reduce this price 
differential by making comparisons between websites 
easier, and removing unsubstantiated claims.
Key communication requirements
It is important that all test users are given adequate and 
appropriate information to help them make safe and 
informed choices. We identified five key communication 
issues with websites selling direct to consumer home- 
sampling COVID-19 tests. All five of these issues may be 
improved by developing a basic framework of what infor-
mation should be provided, and standard ways to present 
such information. This would also facilitate comparison 
between websites.
The type of test and the questions which it can help address
It is essential that companies selling tests identify the type 
of test, and the situations in which it is appropriate to 
order such a test. While websites were clear whether they 
were selling molecular or antibody tests, they also need to 
indicate the situations when it is appropriate to order a 
molecular “swab” test or an antibody “blood” test in order 
to select the correct one. The two US websites used ques-
tionnaires recording symptoms and exposure which were 
reviewed by clinicians prior to tests being despatched, 
which provides a more rigorous check on whether the test 
request is sensible.
How and when the test should be used
Both molecular and antibody tests need to be used at 
different time points in the disease course. The sensitivity 
of both types of tests will fall if used at the wrong time 
point (sensitivity of 31% for antibody tests in the first week 
since onset of symptoms,3 substantially increasing the risks 
of infection or antibody response being undetected). 
Recommended time points when samples should be 
taken were absent for 10/39 UK tests (26%). Some timing 
statements were misleading, suggesting using the test at 
time points which are known to be too early or too late. 
Some websites stated dates based on time since exposure, 
others since symptom onset which is median 5 days after 
exposure. Both are required to be able to advise both 
asymptomatic patients and patients with unknown expo-
sure when they should order and use the tests.
Websites must also describe the full testing process and 
clearly indicate what is required of users to complete 
testing. For example, two antibody websites currently 
indicate that purchasers will need to identify individuals 
qualified to take venous blood samples, which is imprac-
tical for most people.
The test name, evidence of its accuracy, and evidence of its 
regulatory approval for the purpose to which it is put
The majority of tests were for sale by third parties, ranging 
from healthcare providers to beauty treatment specialists. 
In most cases (32/41; 78%) it was not possible to iden-
tify the test being used or the manufacturer. This does 
not allow the individual to know the product that they 
are buying, and precludes the opportunity for the user 
to verify its regulatory status and the claims being made.
Information on test accuracy was absent or uninterpre-
table for 12/41 (29%) tests. Numerical accuracy claims 
could only be matched to published evidence for 4/41 
(10%) of tests. In these instances, figures most closely 
matched those from the manufacturers’ IFU leaflets, 
which tended to report the highest observed values of 
sensitivity and specificity, and were based on studies 
more akin to analytic validity than clinical validity eval-
uations. Accuracy measures from analytic validity studies 
Website Status Comments
MyHealthcare Clinic29 Withdrawn/ suspended "We have unfortunately had to withdraw the PHE Approved 
Antibody Home Testing Kits, per the unexpected Government / 
MHRA ruling on 26 May re private testing. We do not currently 
have a date for when these Home Tests will be next available to 
private patients.”
Medichecks37 Withdrawn/ suspended “Currently, the only way to get a private coronavirus antibody test 
is to buy a venous blood test where you will need to visit a nurse 
or health professional to have a sample collected from a vein in 
your arm. All private laboratories and private testing companies 
have paused self- collect finger- prick testing while the MHRA 
conducts its review. However, we are confident that this service 
will resume shortly once the laboratories have completed their 
validation studies.”
Babylon39 Withdrawn/ suspended “Important update on COVID-19 Antibody Tests. The MHRA (the 
government regulator responsible for medicines and medical 
devices) has asked that all COVID-19 antibody testing from finger- 
prick blood samples be paused. The MHRA decision has impacted 
all testing of this type nationwide.”
“The lab will not be offering further testing services until the MHRA 

















pen: first published as 10.1136/bm






14 Taylor- Phillips S, et al. BMJ Open 2020;10:e042453. doi:10.1136/bmjopen-2020-042453
Open access 
should not be assumed to give a good representation of 
test accuracy when applied in practice to the public. A 
wide range of terms were used, several of which did not 
have a clear meaning. It appeared that test accuracy data 
is not available at all for some tests (Randox),42 or only 
based on contrived samples (Primerdesign)43 and not 
on real patients. For molecular COVID-19 tests, no clin-
ical performance data were available that were based on 
self- sampled swab tests. Withholding the fact that there is 
no patient- based evidence of the accuracy of these tests 
from the public is unacceptable. It is important that the 
reported accuracy is based on all reviewed evidence and 
not selected results, and clearly explains how applicable 
the evidence is to the public.
Naming tests is essential to be able to check their regu-
latory status. Seven of 18 (39%) UK websites selling anti-
body tests inappropriately claimed CE marking, when 
the CE marking was for a different intended use (venous 
rather than finger- prick blood samples). Antibody tests 
are not approved for home use in the USA, and none 
were found in our search. The UK regulator acted after 
we had reviewed UK websites, clarifying that antibody 
tests which are approved for the use with venous samples 
should not be sold for the use with finger- prick samples. 
However, 2/18 remain available for online sale at the 
point of going to press (accessed 11 to 12 June 2020). The 
molecular tests we could identify are approved for home 
sampling, however, the name and manufacturer was not 
identifiable for most websites.
What test results mean
Research concerning the communication of test accu-
racy evidence is limited and is largely restricted to self- 
selected, professional, and postgraduate student groups.51 
Communication of test accuracy evidence is complex for 
several reasons. Research has highlighted the importance 
of communicating the potential consequences of positive 
and negative test results (use of predictive values) and the 
importance of contextualising estimates of accuracy with 
reference to a healthcare setting (for example, hospital in 
patient, hospital outpatient, community).52 53 Presenting 
test accuracy as frequencies rather than as probabilities 
improves understanding.
To interpret results, test users need to know how to 
interpret positive and negative test results (predictive 
values), not the proportion of cases detected (sensitivity) 
and non- cases correctly diagnosed (specificity). Positive 
predictive value was only reported for 5/41 (12%) tests, 
and in all five they claimed it was 100% which is inconsis-
tent with the broader evidence base. Negative predictive 
value was not reported at all.
Most websites gave insufficient information regarding 
the interpretation of test results. Only 8/23 (35%) 
websites explained that a negative molecular virus test 
does not rule out COVID-19, and only 12/18 (67%) 
explained that a positive antibody test does not neces-
sarily infer immunity from future COVID-19 infection or 
transmission.
Decisions which could be made based on the test results
Misunderstanding of the implications of test results could 
mean that individuals put themselves or others at risk 
of infection in the mistaken belief that they do not have 
COVID-19, or that they are immune to COVID-19. This 
last category probably has the greatest potential for harm. 
Clear communication about the meaning of test results 
as detailed above should be linked to evidence- based 
guidance about behaviour modification in light of test 
results. We found widespread evidence of websites failing 
to provide such evidence- based guidance, and some cases 
of websites actively suggesting unsafe behaviour.
CONCLUSIONS
At the point of online purchase of home self- sampling 
COVID-19 tests, users in the UK are provided with 
incomplete, and, in some cases, misleading information 
on test application, accuracy, and interpretation. Many 
websites omit trustworthy guidance on the timing of tests, 
the interpretation of positive and negative test results, 
and the implications of results. Best practice guidance 
for communication about tests to the public should be 
developed and the role of the regulator in enforcing 
complete and accurate information should be reviewed. 
This should be underpinned by robust collaborative qual-
itative research exploring how members of the public 
interpret information and measures of accuracy, thus 
informing how it can be provided in a way that is clear, 
complete, and accessible.
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